drugset / Trial / NCT05016869
Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
This phase I/II study was designed to evaluate the efficacy and safety of fruquintinib combination with capecitabine in maintenance treatment after first-line chemotherapy combined with cetuximab.
Timeline
- Start
- 2022-04-12
- Primary completion
- 2023-02
- Completion
- 2024-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Fruquintinib | Small molecule | 3 mg | Oral |
| Subject | Fruquintinib | Small molecule | 4 mg | Oral |
| Subject | Fruquintinib | Small molecule | 5 mg | Oral |